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Abstract: The genetic architecture of placental abruption (PA) remains poorly understood. We examined variations 
in SNPs of circadian clock-related genes in placenta with PA risk. We also explored placental and maternal genomic 
contributions to PA risk. Placental genomic DNA samples were isolated from 280 PA cases and 244 controls. Ge-
notyping was performed using the Illumina Cardio-MetaboChip. We examined 116 SNPs in 13 genes known to 
moderate circadian rhythms. Logistic regression models were fit to estimate odds ratios (ORs). The combined effect 
of multiple SNPs on PA risk was estimated using a weighted genetic risk score. We examined independent and joint 
associations of wGRS derived from placental and maternal genomes with PA. Seven SNPs in five genes (ARNTL2, 
CRY2, DEC1, PER3 and RORA), in the placental genome, were associated with PA risk. Each copy of the minor allele 
(G) of a SNP in the RORA gene (rs2899663) was associated with a 30% reduced odds of PA (95% CI 0.52-0.95). 
The odds of PA increased with increasing placental-wGRS (Ptrend<0.001). The ORs were 1.00, 2.16, 3.24 and 4.48 
across quartiles. Associations persisted after the maternal-wGRS was included in the model. There was evidence of 
an additive contribution of placental and maternal genetic contributions to PA risk. Participants with placental- and 
maternal-wGRS in the highest quartile, compared with those in the lowest quartile, had a 15.57-fold (95% CI 3.34-
72.60) increased odds of PA. Placental variants in circadian clock-related genes are associated with PA risk; and the 
association persists after control of genetic variants in the maternal genome.
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Introduction
Circadian rhythms are present in virtually all 
organs including those of the reproductive sys-
tem [1]. In mammals, the suprachiasmatic 
nucleus (SCN) of the hypothalamus is the mas-
ter clock, which can synchronize other periph-
eral tissue clocks via endocrine, autonomic and 
behavioral cues. In both the SCN and peripher-
al tissues, the circadian oscillation depends on 
a transcription/translation feedback loop of a 
group of genes collectively named “clock 
genes”. This family of clock genes include the 
transcription factors BMAL1 (also known as 
ARNTL) and CLOCK and proteins encoded by 
genes PER1-3, CRY1-2 and enzyme casein 
kinase 1 epsilon (CSNK1E) [2]. Mutations in any 
of the clock genes can cause severe disrup-
tions in circadian rhythm [3]. The heterodimer 
composed of CLOCK-BMAL1 protein is a posi-
tive regulator and binds to the E-box sequences 
(CACGTG) of the promoters of PER and CRY, 
inducing their expression. The negative regula-
tor is a complex of the proteins PER and CRY 
which translocates to the nucleus and by pro-
tein-protein interaction with CLOCK-ARNTL 
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inhibits the transcription of PER and CRY. 
Translocation to the nucleus PER and CRY 
requires the formation of a complex with 
CSNK1E and provides a delay in the system to 
achieve a period of 24 hours [4]. 
Emerging evidence indicates that the placenta 
may have a functional circadian rhythm and 
that clock genes are expressed across the 
maternal-placental interface [5-9]. For exam-
ple, the existence of the functional placental 
circadian clock is supported by a study that 
showed that HTR/SVneo human primary cells 
are synchronized in vitro by serum shock [5]. 
Furthermore, investigators have documented a 
circadian rhythm pattern of expression of 
CLOCK and BMAL1 (ARNTL) genes in full-term 
human placental explants [9]. These findings, 
together with observations linking circadian 
disruption with preterm delivery [10] and pla-
cental abruption [11] suggests that variants in 
clock-related genes in placental tissues - the 
specific target organ involved in placental 
abruption - may play an independent etiological 
role in the pathogenesis of this complication of 
pregnancy. In a recent study, we documented 
the cumulative association of maternal circadi-
an rhythm related gene variants, in the mater-
nal genome, with an increased risk of placental 
abruption [12].
We hypothesized that variations in single nucle-
otide polymorphisms (SNPs) of circadian clock-
related genes in the placental genome may be 
independently associated with placental abrup-
tion risk. Furthermore, given the unique biologi-
cal interactions and microenvironment at the 
maternal-placental interface, we also explored 
potential interactions of variations in circadian 
clock-related genes in both placental and 
maternal genomes. 
Materials and methods
Study setting and population
The current analyses were conducted using 
data from two case-control studies completed 
by the Peruvian Abruptio Placentae Epide- 
miology (PAPE) study group. The studies have 
been previously described [12-14]. Briefly, hos-
pital admission and delivery logs were moni-
tored daily to identify placental abruption cases 
among new admissions to antepartum, emer-
gency room, and labor and delivery wards of 
participating hospitals. Placental abruption 
was diagnosed based on evidence of retro-pla-
cental bleeding (fresh blood) entrapped 
between the decidua and the placenta or blood 
clots behind the placental margin and accom-
panied by any two of the following: (i) vaginal 
bleeding in late pregnancy not due to placenta 
previa or cervical lesions; (ii) uterine tender-
ness and/or abdominal pain; and, (iii) non-reas-
suring fetal status or fetal death. Controls were 
randomly selected from among pregnant 
women who delivered at participating hospitals 
during the study period and did not have a diag-
nosis of placental abruption in the current preg-
nancy. A total of 280 abruption cases and 244 
controls provided placental specimens. A sub-
set of these cases and controls that also pro-
vided maternal DNA samples (222 placental 
abruption cases and 198 controls) were also 
included in exploratory analyses designed to 
assess the independent and joint contributions 
of maternal and placental genetic variants to 
placental abruption risk.
Ethical approval for both studies was granted 
by the Institutional Review Boards (IRB) of all 
hospitals in Lima, Peru and the IRB of Swedish 
Medical Center, Seattle, WA. All participants 
provided written informed consent.
Data collection, DNA extraction and genotyp-
ing
Standardized structured questionnaires admin-
istered by trained research personnel were 
used to collect information on socio-demo-
graphic characteristics, and medical history. 
Medical records were reviewed to abstract 
information on the course and outcomes of the 
pregnancy. Placental tissue was collected 
immediately after delivery. The chorionic plate, 
including overlying membranes, was removed 
and tissue biopsies were taken from the villous 
tissue, which consists of the intervillous tis-
sues and chorionic villi on the fetal side of the 
placenta. Biopsies of approximately 0.5 cm3 
were taken from a lateral position, approxi-
mately one-third the distance from the placen-
tal edge. Biopsies were placed in cryotubes 
containing RNAlater (Qiagen Inc., Valencia, CA) 
at 10 ml per 1 mg of tissue and stored at -80°C. 
The GentraPureGene Cell kit for DNA prepara-
tions (Qiagen, Hilden, Germany) was used to 
extract DNA from placental specimens. 
Genotyping was conducted using the Illumina 
Variations of circadian clock genes and placental abruption risk
34 Int J Mol Epidemiol Genet 2016;7(1):32-40
Cardio-MetaboChip (Illumina Inc., San Diego, 
CA) platform, a high-density custom array 
designed to include 217,697 SNPs that repre-
sent DNA variations at regions previously relat-
ed to diseases and traits relevant to metabolic 
and atherosclerotic-cardiovascular endpoints 
[15]. During the assay manufacturing process 
20,972 SNPs (9.6%) failed, resulting in 196,725 
SNPs available for genotyping, downstream 
quality control and statistical analyses. 
Candidate gene, SNP selection & data quality 
control
For this candidate gene association study, 13 
genes (PER2, PER3, CLOCK, ARNTL, ARNTL2, 
CRY1, CRY2, CSNK1E, RORA, RORB, RORC, 
NAPS2, DEC1) that were involved in circadian 
clock gene regulation (based on literature 
review) were identified and a total of 116 SNPs 
belonging to these genes and represented in 
the Cardio-MetaboChip were included in the 
candidate gene association analyses. Quality 
control and preprocessing were performed on 
the genotype data as described previously [14].
Statistical analysis
We examined general characteristics of the 
study population using mean (standard devia-
tion, SD) for continuous variables and numbers 
(%) for categorical variables. We compared 
maternal characteristics of placental abruption 
cases and controls using Student’s t-test (for 
Table 1. Maternal characteristics of placental abruption cases and controls
Characteristics
Study Groups
P-value2Placental Abruption (N=280) Controls (N=244)
n % n %
Maternal age at delivery (years)1 27.0 ± 6.5 27.3 ± 6.6 0.59
    <20 35 12.5 32 13.1 0.75
    20-34 204 72.8 168 68.9
    ≥35 40 14.3 43 17.6
Gravidity
    1 110 39.3 95 38.9 0.24
    2-3 118 42.1 116 47.5
    ≥4 52 18.6 33 13.5
Nulliparous 115 41.1 95 38.9 0.66
Maternal education ≤ high school 220 78.6 186 762 0.64
Single marital status 49 17.5 38 15.6 0.32
Employed during pregnancy 126 45.0 108 44.3 0.93
Planned pregnancy 114 40.7 99 40.6 0.97
Received no prenatal care 37 13.2 18 7.4 0.03
Did not take prenatal vitamins 82 29.3 65 26.6 0.78
Smoked during pregnancy 12 4.3 5 2.1 0.22
Pre-pregnancy body mass index (kg/m2)1 23.5 ± 3.5 23.9 ± 3.9 0.22
Pre-pregnancy body mass index (kg/m2)
    Lean (<18.5) 14 5.0 8 3.3 0.49
    Normal (18.5-24.9) 178 63.6 149 61.1
    Overweight (25-29.9) 57 20.4 56 22.9
    Obese (≥30.0) 13 4.6 18 7.4
Gestational age at delivery 35.0 ± 4.3 37.8 ± 3.5 <0.001
Preterm delivery (<37 weeks) 164 58.6 51 20.9 <0.001
Infant birthweight (grams) 2357 ± 889 3058 ± 825 <0.001
Stillbirth 68 24.3 2 0.8 <0.001
Perinatal death 92 32.6 8 3.3 <0.001
1Mean ± Standard deviation (SD); 2P-value are from Student’s t test for continuous variables and chi-square test/Fisher’s Exact 
test for categorical variables.
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continuous variables) and chi-square tests or 
Fisher’s exact tests (for categorical variables). 
Univariate logistic regression model was used 
to estimate odds ratio (OR) and 95% confidence 
interval (95% CI) relating each SNP with risk of 
placental abruption. For multiple testing correc-
tions, a false discovery rate (FDR) procedure 
was used [16]. In multivariable analyses, we 
used a lasso logistic regression model to iden-
tify sets of SNPs that are jointly associated with 
the odds of placental abruption [17]. The num-
ber of selected variables was guided by a pen-
alty parameter: the larger the parameter, the 
smaller the selected subset. A 20-fold cross-
validation approach was performed to select 
the penalty parameter and the value yielding 
the smallest prediction error was used. For 
weighted genetic risk score (WGRS) analyses, a 
10-fold cross-validation procedure was imple-
mented to protect against model over-fitting, 
which arises from using the same data to esti-
mate the regression parameters used in com-
puting WGRS and to evaluate the association 
between placental abruption risk and WGRS 
[18]. This 10-fold cross-validation procedure 
respective point estimates and confidence 
intervals. Weighted genetic risk scores (wGRS) 
were computed by multiplying the number of 
selected risk alleles for each locus by its asso-
ciated effect size. 
Once the wGRS were obtained for all individu-
als, study subjects were categorized into four 
groups defined by the quartiles in the controls. 
We fitted a logistic regression model to derive 
ORs and 95% CIs for placental abruption corre-
sponding to wGRS quartiles, with the first quar-
tile as a referent. In multivariable analyses, we 
evaluated linear trends in risk by treating wGRS 
as ordinal variables after assigning a score (i.e., 
1, 2, 3, and 4) to each quartile. 
We derived maternal circadian clock-related 
candidate genes weighted genetic risk scores 
(herein after referred to as maternal-wGRS) as 
previously described [12]. Briefly, the maternal-
wGRS was computed using 65 SNPs identified 
from among the 119 SNPs included in the cir-
cadian rhythm candidate genes pathway that 
were associated with placental abruption 
Table 2. Top 20 SNPs in univariate analyses of circadian rhythm candi-
date genes from placental tissue in relation to risk of placental abruption
Genes Chromo-some SNPs
Minor 
Allele MAF OR (95% CI)
Empirical 
P-value
ARNTL2 12 rs16931937 G 0.01 2.36 (0.92-6.09) 0.06674
ARNTL2 12 rs1256955 C 0.23 1.21 (0.91-1.61) 0.1845
CRY2 11 chr11:45829415 A 0.03 2.33 (1.29-4.21) 0.003994
CRY2 11 chr11:45849748 G 0.02 0.21 (0.06-0.76) 0.008928
CRY2 11 chr11:45835169 A 0.02 0.17 (0.04-0.79) 0.01022
CRY2 11 rs11038695 A 0.02 0.17 (0.04-0.79) 0.01022
CRY2 11 chr11:45833192 A 0.02 0.17 (0.04-0.79) 0.01022
CRY2 11 chr11:45831281 G 0.02 0.17 (0.04-0.79) 0.01022
CRY2 11 chr11:45859770 G 0.02 0.29 (0.09-0.89) 0.02157
CRY2 11 chr11:45825589 A 0.20 0.71 (0.52-0.98) 0.03701
Dec1 9 rs11794627 A 0.16 0.66 (0.46-0.94) 0.01987
PER3 1 rs875994 G 0.27 0.78 (0.59-1.04) 0.08814
RORA 15 rs2899663 G 0.27 0.66 (0.49-0.88) 0.004592
RORA 15 rs1370433 A 0.42 1.26 (0.99-1.61) 0.06303
RORA 15 rs17303530 C 0.31 0.80 (0.61-1.05) 0.1051
RORA 15 rs12908671 A 0.01 1.89 (0.76-4.68) 0.1611
RORA 15 rs341397 A 0.01 2.20 (0.69-7.06) 0.1742
RORA 15 rs726955 A 0.31 0.83 (0.64-1.09) 0.1802
RORA 15 rs340025 A 0.43 0.87 (0.68-1.11) 0.2661
RORA 15 rs8036966 C 0.20 1.18 (0.88-1.59) 0.2698
MAF=Minor Allele Frequency in controls.
was repeated 1,000 
times to account for the 
variability in randomly 
partitioning the data 
into subsamples. The 
procedure consisted of 
randomly partitioning 
the data into 10 equal 
size subsamples, using 
nine of the subsamples 
as training set and the 
left-out one as valida-
tion set, with each sub-
sample being used in 
turn as a test set. For 
each fold, a multivari-
ate logistic regression 
model was fit on the 
training set using the 
SNPs selected from 
multivariate analyses. 
The receiver operating 
characteristics (ROC) 
curve for each of the 
replicates was evaluat-
ed. The estimated eff- 
ect sizes and AUCs over 
the 1,000 replicates 
were used to obtain the 
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[please see reference 12]. To assess the effect 
of placental-wGRS on placental abruption risk 
while controlling for maternal-wGRS, we includ-
ed both placental-wGRS and maternal-wGRS in 
a fully adjusted model, (i.e., models that includ-
ed maternal age, use of prenatal care services, 
preeclampsia status and gestational age at 
delivery). Finally, we examined the extent to 
which the association of placental abruption 
with placental-wGRS is modified by maternal-
wGRS. For these analyses, we fitted another 
fully adjusted model that include placental-
wGRS and maternal-wGRS along with the inter-
action terms for both maternal and placental 
genomes. The global test for effect modifica-
tion was evaluated using a likelihood ratio test. 
Statistical analyses were conducted using 
gPLINK (version 2.050), R (version i386 3.1.2) 
and STATA (Version 13).
Results
Characteristics of placental abruption cases 
and controls are summarized in Table 1. Cases 
and controls were similar with regards to mater-
nal age, gravidity, nulliparity and a number of 
other characteristics.  As expected, cases were 
more likely to deliver preterm and neonates of 
cases, as compared with controls, were smaller 
and had a higher level of perinatal mortality. 
Table 2 presents the top 20 individual SNPs (in 
genes in the circadian rhythm candidate path-
way) in the placental genome that are associ-
ated with placental abruption, in univariate 
logistic regression analyses. Using lasso logis-
tic regression procedures, we identified 7 SNPs 
in, placental DNA, among the circadian rhythm 
candidate genes pathway (Table 3). Of note, 6 
of these SNPs had empirical P-values<0.05 
0.627 (95% CI 0.626-0.627) for the selected 
model including 7 SNPs, confirming that the 
models has relatively good predictive ability for 
placental abruption risk.
We computed a placental wGRS (i.e., placental-
wGRS) using the 7 SNPs in, placental DNA, 
involved in the circadian rhythm candidate 
genes pathway. Mean placental-wGRS values 
were higher for placental abruption cases as 
compared with controls (5.63 vs. 5.35, 
P<0.001). As shown in Table 4, the odds of pla-
cental abruption increased across each suc-
cessive quartile of the placental-wGRS 
(Ptrend<0.001). Multivariable-adjusted ORs for 
abruption were 1.00, 2.16, 3.24 and 4.48 
across successive quartiles of the placental-
wGRS. Furthermore, we noted that women with 
very high placental-wGRS (i.e., those with a 
wGRS≥5.99, the upper decile) had a 6.60-fold 
(95% CI 2.96-14.70) increased odds of placen-
tal abruption as compared with women who 
had a placental-wGRS<4.98 (i.e., the lowest 
quartile).
To determine associations of placental circadi-
an rhythm candidate genes variants with pla-
cental abruption risk, controlling for maternal 
circadian rhythm candidate gene variants, we 
included both the placental-wGRS and mater-
nal-wGRS in fully logistic regression models 
that included adjustment for possible con-
founding by maternal age, utilization of prena-
tal care, preeclampsia status and gestational 
age at delivery. The ORs for placental abruption 
for successive placental-wGRS quartiles were: 
1.00, 2.44, 3.06, and 5.02 (Ptrend<0.001). The 
corresponding ORs for successive maternal-
wGRS quartiles were: 1.00, 1.37, 2.36, and 
Table 3. Multiple logistic regression based on SNPs selected from 




Allele MAF OR (95% CI)
Empirical 
P-value
ARNTL2 12 rs16931937 G 0.01 2.85 (1.03-7.90) 0.044
CRY2 11 chr11:45849748 G 0.02 0.22 (0.06-0.75) 0.015
CRY2 11 chr11:45829415 A 0.03 2.09 (1.13-3.87) 0.019
CRY2 11 chr11:45825589 A 0.20 0.68 (0.48-0.96) 0.027
DEC1 9 rs11794627 A 0.16 0.64 (0.44-0.94) 0.022
PER3 1 rs875994 G 0.27 0.76 (0.57-1.02) 0.069
RORA 15 rs2899663 G 0.27 0.70 (0.52-0.95) 0.020
MAF=Minor Allele Frequency in controls.
(rs16931937 (ARNTL2), 
rs11794627 (DEC1), rs- 
875994 (PER3) and rs- 
2899663 (RORA)). For 
example, a common SNP 
(minor allele frequency= 
27%) in the RORA gene 
(rs2899663) G+ allelic 
status was found to be 
associated with a 30% 
reduced odds of placental 
abruption (95% CI 0.52-
0.95). The cross-validated 
area under the curve 
(AUC) was estimated to be 
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Table 4. Odds ratio (OR) and 95% confidence interval (CI) for placental abruption in relation to catego-
ries of placental weighted genetic risk score (placental-wGRS) computed from placental candidate 
circadian rhythm genes SNPs selected in multivariable analyses 
Placental Circadian Rhythm Genes 









n (%) n (%)
Quartile 1 (<4.98) 4.79 28 (10.0) 65 (26.6) 1.00 (referent) 1.00 (referent)
Quartile 2 (4.98-5.35) 5.27 60 (21.4) 64 (26.2) 2.18 (1.24-3.83) 2.16 (1.17-3.98)
Quartile 3 (5.36-5.66) 5.59 71 (25.4) 54 (22.1) 3.05 (1.73-5.38) 3.24 (1.77-5.94)
Quartile 4 (≥5.67) 5.98 121 (43.2) 61 (25.0) 4.60 (2.68-7.90) 4.48 (2.51-7.98)
P-value for linear trend  <0.001 <0.001
Quartile 1 (<4.98) 4.79 28 (10.0) 65 (26.6) 1.00 (referent) 1.00 (referent)
≥90% decile (≥5.99) 6.33 50 (17.9) 18 (7.4) 6.45 (3.21-12.95) 6.60 (2.96-14.70)
*Adjusted for maternal age, received prenatal care, preeclampsia status and gestational age at delivery.
Figure 1. The joint effect of placental and maternal weighted genetic risk scores computed from candidate circadian 
rhythm genes SNPs on placental abruption (PA) risk. Bars indicate the odds ratios (OR).
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3.62 (Ptrend<0.001). The findings indicate that 
variants in both placental and maternal 
genomes contribute to placental abruption risk. 
We also fitted another model with interaction 
terms for both placental and maternal wGRS. 
We observed that odds of placental abruption 
was greatest for subjects in the highest quar-
tiles of both the placental and maternal wGRS 
(OR=15.57; 95% CI 3.34-72.60) as compared 
with those in the lowest quartiles for both 
scores (the reference group) (Figure 1). 
However, given our relatively small sample size, 
we observed no evidence of a statistically sig-
nificant interaction (P-value=0.884).
Discussion
The current study adds to the sparse literature 
on the role of variations in circadian clock-relat-
ed genes in the pathogenesis of placental 
abruption.  We identified some SNPs in clock-
related genes (e.g., rs2899663 in the RORA 
gene) in the placental genome that are associ-
ated with placental abruption risk, and these 
associations remained when genetic variations 
in clock-related genes in the maternal genome 
are accounted for in multivariable logistic 
regression models. These results are consis-
tent with and extend findings that we reported 
concerning placental abruption risk in relation 
to genetic variations in clock-related genes in 
the maternal genome [12]. For example, the 
common SNP (minor allele frequency=27%) in 
the RORA gene (rs2899663) G+ allelic status 
was associated with a 30% reduced odds of 
placental abruption (OR=0.70, 95% CI 0.52-
0.95) in the current study, while the same SNP 
(in the maternal genome) was associated with 
20% reduced risk of placental abruption 
(OR=0.80, 95% CI 0.61-1.04) [12]. The RORA 
gene encodes RAR-related orphan receptor A, 
which is a member of the NR1 subfamily of 
nuclear hormone receptors. RORA is a novel 
gene that is related to autism disorder [19]. Two 
other SNPs in RORA (rs1482057 and 
rs12914272) were previously associated with 
breast cancer risk, possibly due to the interac-
tion of circadian clock gene variants and night-
shift work with reproductive hormones [20]. A 
SNP in CRY2 chr11:45829415 (A+ allelic sta-
tus) was associated with 2.09-fold (P-value= 
0.019) increased risk of placental abruption in 
the current study, while the same SNP in the 
maternal genome was associated with 1.72-
fold (P-value=0.088) increased odds of placen-
tal abruption [12]. The CRY2 gene encodes 
cryptochrome circadian clock 2, a flavin ade-
nine dinucleotide-binding protein that is a key 
component of the circadian core oscillator com-
plex, which regulates the circadian clock. The 
CRY2 gene is up-regulated by CLOCK/ARNTL 
heterodimers and is known to represses this 
up-regulation in a feedback loop using PER/
CRY heterodimers to interact with CLOCK/
ARNTL [2]. Of note, altered expression level of 
the CRY2 gene has been observed in pregnan-
cies affected by medically complicated preg-
nancies including gestational diabetes mellitus 
[21].
Our observation adds to the extant literature 
documenting the importance of clock-related 
genes in placental function and disorders [5-7]. 
For example, Frigato et al. investigated the 
expression clock genes in human placenta, and 
demonstrated a circadian expression pattern 
for PER2 and DEC1 transcripts in in vitro syn-
chronized HTR/SVneo cells established from a 
human first trimester extra villous trophoblast. 
Notably, the authors reported that circadian 
oscillations persisted and were even enhanced 
in cells experimentally rendered hypoxic [5]. Of 
note, hypoxemia is considered important in the 
pathogenesis of placental abruption.  
To the best of our knowledge this is the first 
study to explore the joint and independent con-
tributions of variants in clock-related genes in 
both placental and maternal genomes on pla-
cental abruption risk. Despite our relatively 
small sample size, given the unique biological 
intersection of two distinct genomes at the 
maternal-placental interface, we also explored 
potential interactions of variations in circadian 
clock-related genes in both placental and 
maternal genomes. We found that the cumula-
tive association of placental circadian clock-
related gene variants, in the placental genome, 
was associated with increased odds of placen-
tal abruption, even after adjusting for variations 
in the circadian clock-related gene pathway 
ways in the maternal genome. Further, we 
found that the odds of placental abruption was 
particularly high among subjects in the highest 
quartiles of both placental- and maternal 
wGRS. Larger studies are needed to corrobo-
rate these preliminary findings and to further 
elucidate the independent and joint contribu-
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tions of genetic variants in maternal and fetal 
genomes to the pathogenesis of placental 
abruption.
Our findings must be interpreted while consid-
ering some additional limitations. First, we 
used the same dataset to identify SNPs that 
constitute the wGRS and test associations of 
wGRS with placental abruption. Although we 
attempted to assess the predictive validity of 
wGRS by conducting repeated ten-fold cross-
validation, we recognize that inferences from 
our analyses will be enhanced when we are 
able to validate our findings and evaluate the 
predictive power of both the placental and 
maternal wGRS in independent samples of pla-
cental abruption cases and controls [22]. 
Second, we used a research operational defini-
tion of placental abruption which may have led 
to some degree of misclassification. For 
instance, sub-clinical cases of placental abrup-
tion (i.e., those not presenting with abnormal 
vaginal bleeding) may be missed or misclassi-
fied among controls. Consequently, observed 
associations may be conservative. Lastly, the 
generalizability of our findings should be con-
firmed in studies that are conducted in other 
geographically and ethnically diverse popula-
tions of obstetric patients. 
In conclusion, genetic variants in circadian 
clock-related genes in placenta may contribute 
to the pathogenesis of placental abruption, and 
this contribution is independent and possibly 
additive to the contributions of variants in 
clock-related genes in the maternal genome. 
Larger molecular epidemiology studies that 
interrogate the independent and joint contribu-
tions of genomes at the maternal-placental 
interface are needed to confirm our findings 
and to further elucidate the pathogenesis of 
placental abruption.
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